Targeted drug shows promise for multiple Hard-to-Treat cancers

NCT ID NCT07192068

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 33 times

Summary

This study tests a drug called zanidatamab in adults whose cancers have a specific change in the HER2 gene. It includes people with lung, colorectal, endometrial, head and neck, or sarcoma cancers that have not responded to other treatments. The main goal is to see if the drug can shrink tumors. Participants receive the drug by IV every three weeks and are monitored regularly for side effects and disease changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Chu Timone
RECRUITING

Marseille, France

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Gustave Roussy
RECRUITING

Villejuif, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut de Cancérologie de Lorraine
ACTIVE_NOT_RECRUITING

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest
ACTIVE_NOT_RECRUITING

Angers, France

Conditions

Explore the condition pages connected to this study.

COLORECTAL CARCINOMA ENDOMETRIAL ENDOMETRIAL HEAD &AMP; NECK CANCER NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER SARCOMA